Medicine and Dentistry
Overall Survival
69%
Malignant Neoplasm
68%
Colorectal Carcinoma
59%
Rectum Cancer
49%
Systemic Therapy
43%
Neoplasm
42%
Chemoradiotherapy
38%
Gastroesophageal Junction
36%
Circulating Tumor DNA
36%
Pancreas Cancer
35%
Metastatic Colorectal Cancer
35%
Disease Free Survival
32%
Head and Neck Cancer
32%
Lymphocyte
32%
Tumor Biopsy
28%
Body Mass Index
26%
Progression Free Survival
26%
Radiation Therapy
24%
Immune Checkpoint Inhibitor
23%
Hazard Ratio
22%
Neck
21%
Gemcitabine
21%
Oxaliplatin
21%
Histopathology
21%
Treatment Response
20%
Programmed Death 1 Ligand 1
20%
Immunotherapy
19%
Positron Emission Tomography-Computed Tomography
19%
First-Line Chemotherapy
18%
Abdominal Cancer
17%
Microsatellite Instability
17%
Stomach Adenocarcinoma
16%
Receptor
16%
Neoadjuvant Therapy
16%
Squamous Cell Carcinoma
16%
DNA Determination
16%
B-Cell Chronic Lymphocytic Leukemia
16%
B Lymphocyte Receptor
16%
Phosphotransferase Inhibitor
16%
Colon Cancer Stage
16%
Paclitaxel
16%
Mantle Cell Lymphoma
16%
Fluorodeoxyglucose F 18
16%
Neurologic Disease
16%
Neutrophil
16%
Paraneoplastic Cerebellar Degeneration
16%
Survival Prediction
16%
Oncology
16%
Cholangiocarcinoma
16%
Hu Antibody
16%
Pharmacology, Toxicology and Pharmaceutical Science
Chemotherapy
100%
Overall Survival
57%
Circulating Tumor DNA
49%
Neoplasm
43%
Malignant Neoplasm
37%
Head and Neck Cancer
32%
Pancreas Cancer
32%
Disease Free Survival
28%
Breast Cancer
23%
Tumor Marker
23%
Progression Free Survival
21%
Systemic Treatment
20%
Metastatic Colorectal Cancer
19%
Programmed Death 1 Ligand 1
18%
Rectum Cancer
16%
Epidermal Growth Factor Receptor 2
16%
Gamma Urogastrone
16%
Trastuzumab
16%
Squamous Cell Carcinoma
16%
B Lymphocyte Receptor
16%
Phosphotransferase Inhibitor
16%
Chronic Lymphatic Leukemia
16%
Atezolizumab
16%
Pertuzumab
16%
Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
16%
Fluorodeoxyglucose F 18
16%
Non Small Cell Lung Cancer
16%
Curcumin
16%
Advanced Cancer
16%
Polyethylene Terephthalate
16%
Epirubicin
16%
C Reactive Protein
16%
Chronic Myelomonocytic Leukemia
16%
Bile Duct Carcinoma
16%
Survival Prediction
16%
Cancer Staging
16%
Tolerability
16%
Colon Carcinoma
16%
Placebo
16%
Denosumab
16%
Aflibercept
16%
Abdominal Cancer
14%
Adverse Event
11%
Diseases
10%
Biological Marker
10%
Molecular Target
10%
Carcinoma
10%
Immune Checkpoint Inhibitor
9%
Retrospective Study
8%
Vasculotropin
8%
Biochemistry, Genetics and Molecular Biology
Clonal Evolution
49%
Overall Survival
33%
B Cell
32%
Progression Free Survival
32%
Disease Free Survival
20%
Circulating Tumor DNA
16%
Cancer Staging
16%
Immune Checkpoints
16%
Colon
16%
Dynamics
16%
Subtyping
16%
Pharmacokinetics
16%
Eosin
16%
Positron Emission Tomography-Computed Tomography
16%
Morphology
16%
Solution and Solubility
16%
Blood Level
16%
Deep Sequencing
14%
Microsatellite Instability
10%
Genetic Marker
9%
Genotyping
8%
Cisplatin
8%
ERCC1
8%
XRCC1
8%
SLCO1B3
8%
ERCC2
8%
Genetic Polymorphism
8%
Fluorouracil
8%
Next Generation Sequencing
6%
Genetics
6%
Germ Cell
5%
Cell Genetics
5%
Intestine Flora
5%
Tumor Progression
5%
Exon
5%
Immunocompetent Cell
5%
Structural Genomics
5%
Copy Number Analysis
5%
Single Nucleotide Polymorphism
5%
Germline
5%
Immune Evasion
5%
DNA Mismatch Repair
5%
Gene Mutation
5%
